Analytical Data
-
基因名
CD39L1/ENTPD2
-
简介
CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (Active, CHO, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by CHO, with C-His labeled tag.
- Application
-
别名
Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39l1
-
种属
Human
-
表达系统
CHO
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y5L3
-
表达区间
T29-D460
-
分子量
36-37 kDa & 57-63 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD39L1, also known as ENTPD2, is a member of the ecto-nucleotide triphosphate diphosphohydrolase family, primarily involved in the hydrolysis of extracellular ATP and ADP to AMP, thereby playing a crucial role in regulating purinergic signaling in various physiological and pathological contexts. The enzyme's activity is particularly significant in immune responses, where it modulates inflammation and cell proliferation by controlling nucleotide concentrations in the extracellular space. Dysregulation of CD39L1 has been implicated in several diseases, including cancer, where it may contribute to immune evasion by promoting an immunosuppressive tumor microenvironment. Due to its pivotal role in modulating immune responses, CD39L1 is being explored as a potential therapeutic target for cancer immunotherapy and other inflammatory diseases. Understanding the structural and functional properties of CD39L1 through the study of its recombinant protein is essential for developing effective inhibitors or activators that could modulate its activity. This research could pave the way for novel approaches in cancer treatment and other conditions characterized by altered purinergic signaling.
